TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32138661
Drug: GO treatment
Normalized name: Go-dry
Approvals — FDA: no, EMA: no, PMDA: no
Description: GO treatment
Study: 34210187
Drug: Distraction condition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Distraction condition (distracting concurrent task)
Study: 35970681
Drug: Transdermal fentanyl
Normalized name: fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Transdermal fentanyl patches (TFP)
Study: 35970681
Drug: Non-opioid analgesics
Normalized name: Non-opioid analgesics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-opioid analgesics (NSAIDs)
Study: 36141665
Drug: Integrated Program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated Program for Early Childhood Development (comprehensive early development interventions via bi-weekly home visiting activities and monthly family group activities)
Study: 34189864
Drug: Moxibustion treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxibustion treatment for 8 weeks
Study: 34189864
Drug: Sham moxibustion
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham moxibustion treatment for 8 weeks
Study: 35017774
Drug: Early administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early administration of dexmedetomidine
Study: 35017774
Drug: Late administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Late administration of dexmedetomidine
Study: 34910080
Drug: Multifaceted prevention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multifaceted prevention intervention including structured delirium education, daily assessment of delirium risk factors, and tailored prevention strategies (cognitive, motor, sensory stimulation, etc.)
Study: 38568107
Drug: Etidronate treatment
Normalized name: etidronate
DrugBank: Etidronic acid (DB01077)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Etidronate treatment
Study: 34913487
Drug: Multiple Family
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple Family Therapy (MFT) for 3 months
Study: 32572020
Drug: 40IU self‐administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40IU self‐administered intranasal oxytocin (OT)
Study: 35157053
Drug: Early Treatment
Normalized name: Clearly It!
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early Treatment Study (remote trial)
Study: 32163509
Drug: Basic Body
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic Body Awareness Therapy (BBAT) plus Treatment as Usual (TAU)
Study: 32163509
Drug: Mixed Physical
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed Physical Activity (MPA) plus Treatment as Usual (TAU)
Study: 32449418
Drug: Topical clobetasol
Normalized name: clobetasol Topical Foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical clobetasol plus oral low dose naltrexone (3 mg)
Study: 32449418
Drug: Topical clobetasol
Normalized name: clobetasol Topical Foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical clobetasol plus placebo
Study: 32449418
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose naltrexone (3 mg)
Study: 33771664
Drug: Ipilimumab and
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab and Nivolumab (combined therapy)
Study: 35872584
Drug: Group A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A: Isoniazid 15 mg/kg and rifapentine 750/900 mg weekly for 8 weeks.
Study: 35872584
Drug: Group B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B: Isoniazid [600-(50-body weight)×15] (rounded up) and rifapentine 600/450 mg twice a week for 6 weeks.
Study: 35559249
Drug: Echinacea purpurea
Normalized name: Echinacea purpurea
DrugBank: Echinacea purpurea (DB14239)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Echinacea purpurea extract (Echinaforce®, EF) 2,400 mg daily during prevention cycles
Study: 32473649
Drug: Lidocaine +
Normalized name: Lidocaine + Menthol Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine + Propofol (L + P)
Study: 36135037
Drug: Resistance training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistance training during AC taper week
Study: 34915907
Drug: Comparable serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparable serum concentrations of thyroid hormones and binding proteins between patients and controls
Study: 34915907
Drug: Comparable concentrations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparable concentrations of growth hormone, IGF-I, and IGFBP1 between patients and controls
Study: 36407843
Drug: Oxycodone/Naloxone Prolonged
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone/Naloxone Prolonged Release (OXN PR)
Study: 36407843
Drug: Oxycodone Prolonged
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone Prolonged Release (Oxy PR)
Study: 33075179
Drug: L-arginine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (100 mg/kg TID)
Study: 32493211
Drug: Modified dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified dose of 0.5% isobaric bupivacaine in group U
Study: 32493211
Drug: 2 ml
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 ml of 0.5% isobaric bupivacaine in group C
Study: 36015163
Drug: Kan Jang®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kan Jang® (daily dose of andrographolides—90 mg)
Study: 33741696
Drug: Response to
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Response to treatment at different diagnostic thresholds of maternal glycemia
Study: 34469857
Drug: Adjunctive Reading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive Reading Material (ARM)
Study: 34349181
Drug: High sodium
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High sodium intake (mean 24-h sodium excretion of 3834 mg)
Study: 32878606
Drug: Injection time
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection time < 180 s
Study: 32878606
Drug: Injection time
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection time 180-300 s
Study: 32878606
Drug: Injection time
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection time > 300 s
Study: 33667460
Drug: Continuous Serratus
Normalized name: Fucus serratus extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous Serratus Anterior Plane Block (SAPB) in combination with intravenous flurbiprofen
Study: 33667460
Drug: Patient-controlled intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled intravenous analgesia (Control)
Study: 32197933
Drug: Intravesical hyaluronic
Normalized name: hyaluronate
DrugBank: Hyaluronic acid (DB08818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravesical hyaluronic acid (HA) 40 mg (Hyacyst®) weekly for 4 weeks, then monthly for 3 months
Study: 35810525
Drug: Laughter yoga
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Laughter yoga (8 sessions over 4 weeks, twice a week)
Study: 34840600
Drug: Insulin therapy
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin therapy (10 units per 10 cm² of wound, injected in 1 mL 0.9% saline)
Study: 34403911
Drug: Docetaxel 75
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 75 mg/m2 intravenously on day 1 every 21 days
Study: 34403911
Drug: Docetaxel 75
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 75 mg/m2 intravenously on day 1 plus erlotinib 150 mg/day orally on day 2-16 every 21 days
Study: 33315586
Drug: High volume
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High volume injection without corticosteroids (50 mL saline and lidocaine)
Study: 33315586
Drug: Placebo injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injection (2 mL saline and lidocaine)
Study: 33315586
Drug: High volume
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High volume injection without corticosteroids
Study: 34668986
Drug: Melatonin 10
Normalized name: melatonin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 10 mg daily during menstruation
Study: 37148497
Drug: Antimuscarinic agents
Normalized name: ANTIMUSCARINICS/ANTISPASMODICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimuscarinic agents
Study: 35685657
Drug: Pulsed Radiofrequency
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed Radiofrequency (RF) therapy
Study: 35685657
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin type A (BoNT-A) injection
Study: 35130966
Drug: Action observation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Action observation therapy (AOT) group observing videos of eccentric exercises prior to performing the exercises.
Study: 35752215
Drug: Age-appropriate intervention
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Age-appropriate intervention consisting of problem-solving therapy, behavioral activation, parenting skills training, and parenting support from a self-identified adult
Study: 33305660
Drug: Ticagrelor monotherapy
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor monotherapy (TIC)
Study: 33305660
Drug: Ticagrelor and
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor and Aspirin (TIC+ASP)
Study: 34627141
Drug: concomitant medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: concomitant medication
Study: 32106225
Drug: Housing First
Approvals — FDA: no, EMA: no, PMDA: no
Description: Housing First treatment (rent supplements and mental health support services)
Study: 32199021
Drug: Balneotherapy (BT)
Normalized name: BTS
DrugBank: Pyruvic acid (DB00119)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balneotherapy (BT) plus Physical Therapy (PT)
Study: 36075595
Drug: Chicken‐claw needling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chicken‐claw needling at Xiaguan (ST 7) combined with intradermal needling, once a day for 6 days, total of 2 courses.
Study: 36075595
Drug: Oral carbamazepine
Normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral carbamazepine tablets for 13 days.
Study: 36730056
Drug: Tilavonemab 2000
Normalized name: Tilavonemab
DrugBank: Tilavonemab (DB17014)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tilavonemab 2000 mg
Study: 33609476
Drug: Tilavonemab 4000
Normalized name: Tilavonemab
DrugBank: Tilavonemab (DB17014)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tilavonemab 4000 mg
Study: 36297495
Drug: ADV6209 (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADV6209 (0.25 mg kg−1)
Study: 36297495
Drug: Conventional midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Conventional midazolam (0.25 mg kg−1)
Study: 34486319
Drug: Wheat bran
Normalized name: Wheat bran
DrugBank: Wheat bran (DB10685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wheat bran (40 g per day for 30 days)
Study: 32366796
Drug: PBMT (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: PBMT (all doses)
Study: 32040542
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of herbal medicines in active labour
Study: 32505383
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg linzagolix
Study: 32505383
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg linzagolix
Study: 32505383
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg linzagolix
Study: 32505383
Drug: linzagolix (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: linzagolix (doses ≥ 75 mg)
Study: 33068345
Drug: Oryzanol tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oryzanol tablets and compound vitamin B tablets, 2 tablets each, 3 times daily for 30 days.
Study: 35863457
Drug: Fluconazole (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole (3 sequential 150 mg doses every 72 hours)
Study: 33876875
Drug: L-citrulline (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-citrulline (3 g/day)
Study: 35005777
Drug: Oral drug
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral drug treatment
Study: 35363054
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment arms (AHCL and 670G)
Study: 34103898
Drug: DA-8031 20
Normalized name: guaifenesin
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DA-8031 20 mg
Study: 34103898
Drug: DA-8031 30
Normalized name: DA-8031
DrugBank: DA-8031 (DB19024)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DA-8031 30 mg
Study: 34103898
Drug: DA-8031 40
Normalized name: DA-8031
DrugBank: DA-8031 (DB19024)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DA-8031 40 mg
Study: 35263755
Drug: Once-weekly lonapegsomatropin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly lonapegsomatropin 0.24 mg human growth hormone/kg/week
Study: 35263755
Drug: Daily somatropin
Normalized name: Somatropin
DrugBank: Somatotropin (DB00052)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily somatropin therapy
Study: 33050945
Drug: Famotidine 160
Normalized name: Famotidine
DrugBank: Famotidine (DB00927)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Famotidine 160 mg four times a day for up to 14 days
Study: 33050945
Drug: Placebo in
Normalized name: placebo INTRAVEN VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in the same dosage as Famotidine
Study: 35956324
Drug: Oat bran
Normalized name: Oat bran
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oat bran (30 g/d, containing DF 8.9 g)
Study: 32020530
Drug: Pazopanib 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pazopanib 800 mg once daily (QD)
Study: 32020530
Drug: Pazopanib 400
Normalized name: PAZOPanib 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pazopanib 400 mg twice daily
Study: 33811803
Drug: Self-administration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administration of medication programme
Study: 33811803
Drug: Routine medication
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine medication administration (Control)
Study: 32020567
Drug: Chemotherapy (imatinib,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (imatinib, bevacizumab)
Study: 32020567
Drug: Aggressive multi-modality
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive multi-modality treatment options
Study: 35364066
Drug: Standard triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard triple therapy for H pylori eradication (n=817)
Study: 35364066
Drug: Standard triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard triple therapy for H pylori eradication (n=625 with successful eradication)
Study: 35364066
Drug: Standard triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard triple therapy for H pylori eradication (n=625)
Study: 37258943
Drug: 50 g
Normalized name: glucose 50 g/296 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g whole almonds daily during the intervention period
Study: 33122092
Drug: Sleep Deprivation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sleep Deprivation Treatment (SDT) for 48 hours
Study: 35477594
Drug: d-Amphetamine Transdermal
Normalized name: amphetamine / dextroamphetamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-Amphetamine Transdermal System (d-ATS) 5 mg/9 h, with possible dose increase to 10 mg/9 h, 15 mg/9 h, and 20 mg/9 h during the study
Study: 35477594
Drug: d-Amphetamine Transdermal
Normalized name: amphetamine / dextroamphetamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-Amphetamine Transdermal System (d-ATS)
Study: 35122668
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 supplementation at a dose of 400 IU/d (vD-400 group)
Study: 36303179
Drug: High-flow nasal
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flow nasal cannula (HFNC) at a rate of 60 L/min and a concentration of 100% (n = 87)
Study: 36303179
Drug: Facemask at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Facemask at a rate of 6 L/min and a concentration of 100% (n = 89)
Study: 33472722
Drug: Whole grain
Normalized name: Whole grain barley
DrugBank: Barley (DB10506)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole grain intake (half of grain servings from whole grain foods daily for 6 weeks)
Study: 34347945
Drug: Anti-TNF treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-TNF treatment (both etanercept and adalimumab)
Study: 33481484
Drug: CBD oil
Normalized name: MENTHOL, UNSPECIFIED FORM 10 g in 100 g / CAMPHOR (NATURAL) 3 g in 100 g TOPICAL CREAM [ETERNAL SPIRIT BEAUTY PAINLESS WITH CBD OIL 3000]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBD oil (150 mg POST, 24 h, 48 h)
Study: 33346061
Drug: Participants' satisfaction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants' satisfaction with treatment results
Study: 35693874
Drug: Nonavalent HPV
Normalized name: Adxs hpv
DrugBank: Axalimogene filolisbac (DB16692)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonavalent HPV vaccine
Study: 34144047
Drug: Vedolizumab IV
Normalized name: Vedolizumab
DrugBank: Vedolizumab (DB09033)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Vedolizumab IV 300 mg every 8 weeks
Study: 33573589
Drug: Journeying through
Normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA spike protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Journeying through Dementia (JtD) intervention, consisting of both group and individual sessions, with a therapeutic dose of 10 out of 16 sessions.
Study: 35061237
Drug: Dietary supplement
Normalized name: dietary supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary supplement containing probiotics and botanical extract (group II)
Study: 35061237
Drug: Dietary supplement
Normalized name: dietary supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary supplement (group II)
Study: 35238144
Drug: Topical 0.25%
Normalized name: permethrin topical 0.25% topical kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.25% w/w finasteride spray (1-4 sprays; 50-200 μl/day) for 24 weeks
Study: 35238144
Drug: Once-daily finasteride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily finasteride 1 mg oral tablet for 24 weeks
Study: 35238144
Drug: Twice-daily finasteride
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily finasteride 1% topical gel for 6 months
Study: 35238144
Drug: Once-daily finasteride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily finasteride 1 mg oral tablet for 6 months
Study: 35238144
Drug: Twice-daily finasteride
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily finasteride 0.25% topical solution for 7 days
Study: 32295716
Drug: Bivalirudin (bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalirudin (bolus 0.75 mg/kg followed by an infusion 1.75 mg/kg/h for the duration of the procedure)
Study: 32295716
Drug: Heparin (bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (bolus 70 U/kg)
Study: 34050877
Drug: Potassium citrate
Normalized name: Potassium Citrate
DrugBank: Potassium (DB14500)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Potassium citrate administration
Study: 34050877
Drug: No potassium
Normalized name: No potassium hemofiltration solution
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No potassium citrate administration (Control)
Study: 32616589
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (500 mg·day‐1)
Study: 32791690
Drug: Digital storytelling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital storytelling intervention based on rational emotive behaviour therapy (REBT)
Study: 34658006
Drug: Sarilumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sarilumab plus usual care (including corticosteroids at 1 mg/kg/day for at least 3 days)
Study: 34658006
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care alone (including corticosteroids at 1 mg/kg/day for at least 3 days)
Study: 35557479
Drug: Pregabalin 50
Normalized name: pregabalin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin 50 mg three times a day
Study: 35557479
Drug: Ketotifen 1
Normalized name: ketotifen 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketotifen 1 mg twice a day
Study: 34253208
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy with paclitaxel plus cisplatin for two cycles followed by radical hysterectomy and bilateral adnexectomy
Study: 34253208
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy with radical surgery
Study: 32188988
Drug: Abiraterone acetate
Normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Abiraterone acetate plus prednisone (1000 mg/day and 5 mg/day respectively)
Study: 34981483
Drug: Curcumin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin (500 mg per 12 hours)
Study: 37133765
Drug: Functional Assessment
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional Assessment of Cancer Therapy–Bladder Cancer (FACT-BL)
Study: 32951013
Drug: Vasopressin infusion
Normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vasopressin infusion at a mean dose of 0.3 ± 0.2 mU/kg/min
Study: 34780705
Drug: Quadrivalent HPV
Normalized name: HPV, quadrivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadrivalent HPV vaccine (0.5 mL injection administered on day 1, month 2, and month 6)
Study: 33706033
Drug: CAM-ICU assessments
Normalized name: phendimetrazine tartrate Oral Tablet [Cam-Metrazine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAM-ICU assessments twice daily for 5 days
Study: 33706033
Drug: CAM-ICU assessments
Normalized name: phendimetrazine tartrate Oral Tablet [Cam-Metrazine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAM-ICU assessments twice daily for 4 days
Study: 33706033
Drug: CAM-ICU assessments
Normalized name: phendimetrazine tartrate Oral Tablet [Cam-Metrazine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAM-ICU assessments twice daily for 3 days